Working… Menu
Trial record 1 of 1 for:    TRANSATRA
Previous Study | Return to List | Next Study

Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) (TRANSATRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02717884
Recruitment Status : Recruiting
First Posted : March 24, 2016
Last Update Posted : October 18, 2018
University Hospital Freiburg
Information provided by (Responsible Party):
Michael Luebbert, University Hospital Freiburg

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2021